Last Updated : June 29, 2024
The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Cablivi | caplacizumab | Acquired thrombotic thrombocytopenic purpura (aTTP) | Do not reimburse | Complete | ||
| Cabometyx | Cabozantinib | Renal Cell Carcinoma (RCC) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Cabometyx | Cabozantinib | HCC | Reimburse with clinical criteria and/or conditions | Complete | ||
| Cabometyx | cabozantinib | Differentiated thyroid carcinoma | Reimburse with clinical criteria and/or conditions | Complete | ||
| Cabometyx | cabozantinib | Advanced or metastatic renal cell carcinoma | Reimburse with clinical criteria and/or conditions | Complete | ||
| Caduet | Amlodipine besylate/ atorvastatin calcium | Hypertension/ Dyslipidemia | List with clinical criteria and/or conditions | Complete | ||
| Calquence | Acalabrutinib | Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Calquence | Acalabrutinib | Chronic Lymphocytic Leukemia (CLL) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Campral | Acamprosate calcium | Alcohol Abstinence | List with clinical criteria and/or conditions | Complete | ||
| Campral | Acamprosate calcium | Alcohol Abstinence | N/A | Complete | ||
| Camzyos | mavacamten | Obstructive hypertrophic cardiomyopathy | Reimburse with clinical criteria and/or conditions | Complete | ||
| Caprelsa | Vandetanib | Medullary Thyroid Cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| Carvykti | ciltacabtagene autoleucel | Relapsed or refractory multiple myeloma | Active | |||
| Carvykti | ciltacabtagene autoleucel | Relapsed or refractory multiple myeloma | Reimburse with clinical criteria and/or conditions | Complete | ||
| Cayston | Aztreonam for inhalation solution | Cystic fibrosis, chronic pulmonary pseudomonas aeruginosa infections | List with clinical criteria and/or conditions | Complete | ||
| Celsentri | Maraviroc | HIV | Withdrawn | |||
| Celsentri | Maraviroc | HIV | List with clinical criteria and/or conditions | Complete | ||
| Celsentri | Maraviroc | HIV infection | Do not list | Complete | ||
| Cerdelga | Eliglustat | Gaucher disease | Reimburse with clinical criteria and/or conditions | Complete | ||
| Champix | Varenicline tartrate | Smoking-cessation | List with clinical criteria and/or conditions | Complete | ||
| Cibinqo | abrocitinib | Atopic dermatitis, moderate to severe | Reimburse with clinical criteria and/or conditions | Complete | ||
| Cimzia | certolizumab pegol | Psoriasis, moderate to severe plaque | Reimburse with clinical criteria and/or conditions | Complete | ||
| Cimzia | Certolizumab pegol | Ankylosing spondylitis | List with criteria/condition | Complete | ||
| Cimzia | Certolizumab pegol | Arthritis, psoriatic | List with criteria/condition | Complete | ||
| Cimzia | Certolizumab pegol | Arthritis, rheumatoid | Do not list | Complete |
Last Updated : June 29, 2024